Human anti-TNF antibodies and peptides
AssigneeNew York University
InventorsJunming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Life of this patent
Estimating the term…
Abstract
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Claims43
A human anti-TNF antibody or antigen-binding fragment thereof that competitively inhibits binding of A2 or cA2 to human TNF-α.
A human anti-TNF antibody or antigen-binding fragment thereof, wherein said anti-TNF antibody or antigen-binding fragment binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO:1 of hTNF, as determined by Gysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid.
A human anti-TNF antibody or antigen-binding fragment thereof, wherein said anti-TNF antibody or antigen-binding fragment binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO:1 of hTNF, as determined by Gysen epitope mapping comprising use of TNF dodecapeptide pins which overlap at every second amino acid.
A human anti-TNF antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment has epitopic specificity identical to A2 or cA2.
A human anti-TNF antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment comprises the complementarity determining regions of A2 or cA2.
A human anti-TNF antibody or antigen-binding fragment thereof, comprising an IgG1 constant region, wherein said anti-TNF antibody or antigen-binding fragment competitively inhibits binding of A2 or cA2 to human TNF-α.
A human anti-TNF antibody or antigen-binding fragment thereof comprising an IgG1 constant region, wherein said anti-TNF antibody or antigen-binding fragment binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO:1 of hTNF, as determined by Gysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid.
A human anti-TNF antibody or antigen-binding fragment thereof comprising an IgG1 constant region, wherein said anti-TNF antibody or antigen-binding fragment binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO:1 of hTNF as determined by Gysen epitope mapping comprising use of TNF dodecapeptide pins which overlap at every second amino acid.
A human antibody or antigen-binding fragment thereof, comprising an IgG1 constant region, wherein said antibody or antigen-binding fragment has epitopic specificity identical to A2 or cA2.
A human antibody or antigen-binding fragment thereof, comprising an IgG1 constant region, and wherein said antibody or antigen-binding fragment comprises the complementarity determining regions of A2 or cA2.
A human light chain that specifically binds human TNFα and competitively inhibits binding of A2 or cA2 to human TNF-α, said human light chain consisting of the complementarity determining regions of the light chain of A2 or cA2, and a human light chain framework region.
A human heavy chain that specifically binds human TNFα and competitively inhibits binding of A2 or cA2 to human TNF-α, said human heavy chain consisting of the complementarity determining regions of the heavy chain of A2 or cA2, and a human heavy chain framework region.
Dependencies are inferred from the claim text.